The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review
Open Access
- 27 August 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Virology Journal
- Vol. 9 (1), 174
- https://doi.org/10.1186/1743-422x-9-174
Abstract
Recent observational studies suggest a role for lipopolysaccharide (LPS) as a marker of immune activation in HIV-infected patients, with potential repercussions on the effectiveness of antiretroviral regimens. A systematic review of LPS as a marker of immune activation in HIV-1 infected patients. MEDLINE register of articles and international conference proceedings. Case–control studies comparing the role of plasma LPS as a marker of immune activation in HIV-infected patients versus HIV negative subjects. Two hundred and six articles were selected using MEDLINE, plus 51 studies presented at international conferences. Plasma LPS is a marker of immune activation in HIV-infected patients, determining the entry of central memory CD4+ T cells into the replication cycle and finally generating cell death. Plasma LPS probably results from immune-mediated alterations of the intestinal barrier, which can occur soon after HIV seroconversion. LPS is a likely marker of disease progression, as it drives chronic monocyte activation, and some studies suggest that hyperexpression of CCR5 receptors, related to LPS plasma levels, could be responsible for monocyte trafficking in the brain compartment and for the appearance of HIV-associated neurocognitive disorders. Long-term combination antiretroviral therapy (cART) generally reduces LPS concentrations, but rarely to the same levels as in the control group. This phenomenon probably depends on ongoing but incomplete repair of the mucosal barrier. Only in patients achieving maximal viral suppression (i.e. viral load < 2.5 cp/ml) are LPS levels comparable to healthy donors. In successfully treated patients who did not restore CD4+ T cells, one hypothesis is that the degree of residual microbial translocation, measured by LPS, alters the turnover of CD4+ T cells. LPS is a marker of microbial translocation, responsible for chronic immune activation in HIV-infected patients. Even in successfully treated patients, LPS values are rarely normal. Several studies suggest a role for LPS as a negative predictive marker of immune restoration in patients with blunted CD4 T cell gain.Keywords
This publication has 21 references indexed in Scilit:
- Microbial Translocation: A Marker of Advanced HIV-1 Infection and a Predictor of Treatment Failure?The Journal of Infectious Diseases, 2011
- Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus InfectionsPLoS Pathogens, 2010
- Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapyAIDS, 2010
- Microbial translocation, the innate cytokine response, and HIV-1 disease progression in AfricaProceedings of the National Academy of Sciences of the United States of America, 2009
- Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral‐Treated HIV InfectionThe Journal of Infectious Diseases, 2009
- Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patientsAIDS, 2009
- Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis CGastroenterology, 2008
- Microbial Translocation Is Associated with Increased Monocyte Activation and Dementia in AIDS PatientsPLOS ONE, 2008
- Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of TherapyThe Journal of Infectious Diseases, 2008
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006